

LSU Health Science Center

LSU Health Digital Scholar

---

Medical Research Day

2022 Medical Research Day Posters

---

Oct 13th, 12:00 AM

## In-depth analysis of Next-Generation Sequencing (NGS) and bioinformatics results in pediatric ADGRV1 compound heterozygotes

Sloane Clay

*LSU Health Sciences Center- New Orleans*

Adele Evans

Chindo Hicks

David Otohinoyi

Follow this and additional works at: <https://digitalscholar.lsuhscc.edu/sommrd>



Part of the [Medical Genetics Commons](#)

---

### Recommended Citation

Clay, Sloane; Evans, Adele; Hicks, Chindo; and Otohinoyi, David, "In-depth analysis of Next-Generation Sequencing (NGS) and bioinformatics results in pediatric ADGRV1 compound heterozygotes" (2022). *Medical Research Day*. 16.

<https://digitalscholar.lsuhscc.edu/sommrd/2022MRD/Posters/16>

This Event is brought to you for free and open access by the School of Medicine at LSU Health Digital Scholar. It has been accepted for inclusion in Medical Research Day by an authorized administrator of LSU Health Digital Scholar. For more information, please contact [aolini@lsuhscc.edu](mailto:aolini@lsuhscc.edu).

## Introduction


**BACKGROUND:** Medical evaluation of sensorineural hearing loss (SNHL) is critical to anticipatory guidance, particularly important with syndromic and/or progressive disorders like Usher syndrome (SNHL and retinitis pigmentosa). Genetic diagnosis using next generation sequencing (NGS) proves challenging with multigenic, multiallelic variants of uncertain significance (VUS). Identification and reclassification of VUS is a fluid process, accelerated by genetic testing companies, and thus necessitates in-depth analysis and interpretation. Compound heterozygous variants may be misinterpreted as benign but in fact result in deleterious combined autosomal recessive expression, important to diagnosis.

Variants in ADGRV1 (inherited in a recessive or compound heterozygous manner) have been implicated in Usher Syndrome (Type II). Usher Syndrome Type II presents as SNHL at birth and retinitis pigmentosa (RP) in the second decade of life leading to blindness.

**SIGNIFICANCE:** If variants in genes like ADGRV1 can be identified leading to earlier diagnoses, then patients can receive access to learning resources before their visual and/or hearing impairment becomes too severe.


**HYPOTHESIS:** The ADGRV1 variants present in the cohort contribute to their clinical presentation, along with other genes in which they carry VUS.

## Figure 1: Approach




CHNOLA – Children's Hospital New Orleans,  
SNHL – sensorineural hearing loss

## Figure 2: ADGRV1 Cohort Pedigrees



## Figure 3: ADGRV1 Variant Prediction




The software programs **MutTaster**, **PolyPhen-2**, and **SIFT** perform in-silico analysis of exonic variants and predicts their effects on the protein product.

**CADD** is a pathogenicity score based on functional and evolutionary data (low score = neutral; high score = damaging)  
**PhyloP** score represents the evolutionary conservation of the nucleotide; a positive score means that nucleotide is conserved. Higher scores are considered more deleterious.

**IntSplice** predicts a splicing consequence of a single nucleotide variation (SNV) at intronic positions -50 to -3 close to the 3' end of an intron of the human genome

## Figure 4: IPA Network – Ingenuity Pathway Analysis



## Results

We identified six different ADGRV1 variants in three ethnically diverse families.

### Protein Prediction Summary (Figure 3)

- **Subject 1:** Both variants (1 and 2) predicted as "damaging or deleterious", consistent with current classification.
- **Subject 2:** Both variants (3 and 4) predicted as "damaging or deleterious".
- **Subject 3:** Both variants (5 and 6) predicted as "benign or neutral".

### IPA Analysis Results (Figure 4)

- The network demonstrates a direct binding relationship between ADGRV1 and MYO7A.
- This relationship is supported by the literature. Both genes are involved in Usher Syndrome (Type II).
- Subject 2 has a MYO7A variant along with 2 ADGRV1 variants.
- The implications of Subject 2's variants on ADGRV1-MYO7A binding require further investigation.
- The network demonstrates PEX5 operating in an adjacent network to ADGRV1 and MYO7A.
- Subjects 2 and 3 both have variants in PEX5.
- The implications of Subject 2 and 3 variants on the larger network requires further investigation.

### ADGRV1 Variants - Population Database Results

#### (Figure 5)

Each ADGRV1 variant in our cohort was cross-referenced with 3 population databases (ExAD, gnomAD, and 1000genome).

<b>Subject 1 - Honduran</b> (Variants 1 and 2)	(1) Previously reported, but not in Latin American population (2) Not reported to date
<b>Subject 2 - French Acadian</b> (Variants 3 and 4)	(3) Not reported to date (4) Previously reported, but not in French/Cajun population
<b>Subject 3 - African American</b> (Variants 5 and 6)	Both (5) and (6) previously reported in the African American population

## Conclusion

- VUS should not be misinterpreted as "benign".
- Especially true of compound heterozygotes because diseases like Usher Syndrome are typically characterized as "autosomal recessive" disorders.
- Analysis of VUS using open-source bioinformatics software supports clinicians and researchers in VUS reclassification.
- Our data will be submitted to national genetics databases. As the number of submissions for specific variants grows, the American College of Genetics may reclassify VUS based on the available data.
- It is vital for clinicians to follow up regularly with these patients as variant reclassification is occurring rapidly.
- VUS reclassification enables physicians to provide better anticipatory guidance, ultimately leading to high-quality healthcare and improved academic support for diverse special-needs populations.
- Further investigation regarding the compounding effects of variants (especially VUS) in hearing loss genes must be done in order to understand their potential combined clinical impact.